Imugene Hires Ex-Allogene Exec as Chief Medical Officer to Drive Azer-Cel Trial [VIDEO]
Imugene appoints Chief Medical Officer azer-cel veteran Dr John Le Gall, an allogeneic CD19 CAR T specialist from Allogene, as the single-asset biotech backs a 75% response rate Phase 1b program.
Key Takeaways
- Imugene has appointed Dr John Le Gall as Chief Medical Officer, effective immediately, bringing allogeneic CD19 CAR T experience that matches azer-cel directly.
- Dr Le Gall comes from Allogene, where he redesigned the pivotal development plan for cema-cel, an allogeneic CD19 CAR T therapy.
- Dr John Byon steps down by mutual agreement and stays on as a consultant, with the company expecting no interruption to the azer-cel program.
- The role was restructured because Imugene is now a single-asset company, with Paul Hopper saying the cost base must reflect that focus.
- The appointment lands alongside a 75% overall response rate across 55 Phase 1b patients, though no dates were given for upcoming readouts or regulatory interactions.
![Syntara Drug Slows Motor Decline in Early Parkinson’s Risk Group, Placebo Worsens [VIDEO]](https://media.stockwirex.com/Glowing-SNT-Letters.jpg)
![Imugene’s Blood Cancer Drug Hits 71% Response Rate in Hard-to-Treat BTKi Patients [VIDEO]](https://media.stockwirex.com/Lab-with-IMU-sign.jpg)
![FirstWave Cloud Technology Cuts FY26 Loss 80% With Second Year of Positive Cash Flow [VIDEO]](https://media.stockwirex.com/server-room-display.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer